The occurrence of Type II (non-insulin-dependent) diabetes and obesity and their associated morbidities continue to increase and they are rapidly reaching epidemic proportions. AMPK (AMP-activated protein kinase) was initially thought of as an intracellular 'fuel gauge' responding to a decrease in the level of ATP by increasing energy production and decreasing energy utilization. Recent studies have shown that AMPK plays a role in controlling the whole body energy homoeostasis, including the regulation of plasma glucose levels, fatty acid oxidation and glycogen metabolism. In addition to its effects on the periphery, AMPK has been found to play a key role in the control of food intake through its regulation by hormones, including leptin, within the hypothalamus. The control of AMPK activity, therefore, provides an attractive target for therapeutic intervention in metabolic disorders such as obesity and Type II diabetes. Indeed, a number of physiological and pharmacological factors that are beneficial in these disorders have been shown to act, at least in part, through the activation of AMPK.
Structure of AMPK (AMP-activated protein kinase)
AMPK is a heterotrimeric protein comprising a catalytic α subunit and two regulatory subunits (β and γ ) that have been highly conserved throughout evolution, and homologues of all three subunits have been identified in plants, yeast, nematode worms, flies and mammals [1, 2] . In mammals, multiple forms of each subunit, which are the products of different genes (α1, α2, β1, β2, γ 1, γ 2 and γ 3), exist. All possible combinations of the heterotrimer appear to be expressed in mammals, i.e. 12 different complexes. In addition, alternative splicing of some of the genes and the use of different promoters add to the complexity of the system [2] . Although it is still not completely understood, it is probable that the different isoforms confer both tissue specificity, and specificity in the response to the nature of the stimulus, on the kinase. For instance, the γ 3 isoform is expressed in skeletal muscles, primarily in fast-twitch fibres [3] , where it appears to play a role in the regulation of fuel utilization [4] .
The α subunits contain a protein kinase catalytic domain at the N-terminus and a C-terminal regulatory domain that is involved in binding to the β and γ subunits and also contains an autoinhibitory region [5] . The β subunits contain a glycogen-binding domain that is found in enzymes that metabolize the α1 → 6 branch points in α1 → 4-linked glucans, such as starch and glycogen [6, 7] , but the physiological role of this domain within the β subunits remains unclear. The β subunits Key words: AMP-activated protein kinase, energy homoeostasis, fatty acid oxidation, glucose uptake, LKB1, metabolic syndrome. Abbreviations used: AICAR, 5-amino-4-imidazole carboxamide riboside; AMPK, AMP-activated protein kinase; CBS, cystathionine-β-synthase; KO, knockout; mTOR, mammalian target of rapamycin; NPY, neuropeptide Y; TSC, tuberous sclerosis complex. 1 Correspondence may be addressed to either of the authors (email l.fryer@imperial.ac.uk or dcarling@imperial.ac.uk).
also contain a C-terminal domain that is sufficient to bind to, and form complexes with, the α and γ subunits [6] . The γ subunits contain four domains known as CBS (cystathionine-β-synthase) domains. These domains are found in a wide variety of proteins and usually occur in pairs, and it has been suggested that these tandem repeats of CBS domains be termed Bateman domains [8] , after Alex Bateman who first identified the CBS domain [9] .
Naturally occurring mutations in human γ 2 and pig γ 3 have been identified and these occur in or close to the Bateman domains [2] . Mutations in γ 2 cause cardiac hypertrophy associated with a significant increase in glycogen together with an arrhythmia, similar to the Wolff-Parkinson-White syndrome [10] [11] [12] . A missense mutation in pig γ 3 causes a marked accumulation of glycogen in skeletal muscles [13] . Although the molecular basis for the altered heart and skeletal-muscle metabolism is enigmatic, all the mutations interfere with AMP (and ATP) binding [14, 15] , indicating an important role for the Bateman domains in nucleotide binding. The effect of the mutations on AMPK activity is controversial and some studies have suggested that the mutations are activating [4, 16] , whereas others suggest that they are inactivating [14, 15] . Clearly, further work is required to resolve this issue. Energy intake (food) is used for energy expenditure and any excess is stored in the body, e.g. as fat (adipose) or glycogen (skeletal muscles). The hypothalamus plays a key role in the integration of these pathways by hormones, e.g. insulin secreted from pancreatic β-cells and leptin secreted from adipose cells. AMPK inhibits storage pathways and stimulates energy expenditure. In addition, recent studies indicate that activation of AMPK in the hypothalamus increases food intake, whereas inhibition decreases intake.
mediated by the binding of AMP to AMPK, since LKB1 activity is not affected by AMP [19, 20] .
In addition to this response to changes in cell energy level, recent studies have demonstrated that the AMPK cascade can also be activated in response to stimuli that do not cause a detectable change in the AMP/ATP ratio, including activation in response to hyperosmotic stress [22] and the antidiabetic drug, metformin [22, 23] . The mechanism for this nucleotide-independent activation is not clear but involves phosphorylation of Thr-172 [22, 23] . Pharmacological studies have ruled out the mitogen-activated protein kinase, phosphoinositide 3-kinase and protein kinase C pathways [22] . A more recent study reported that inhibition of LKB1 abolished the activation of AMPK in response to hyperosmotic stress, suggesting that LKB1 is required for nucleotideindependent activation [19] .
Until recently, the identity of the upstream kinase in the AMPK cascade had remained elusive. However, recent findings provide strong evidence that the protein kinase LKB1 is a major AMPKK (AMPK kinase). Initial studies using the yeast homologue of AMPK, SNF1, showed that three closely related protein kinases, Elm1, Pak1 and Tos3, phosphorylate and activate SNF1 [18, 24] . The mammalian proteins most closely related to these are the Ca 2+ /calmodulindependent kinase kinase subgroup. Earlier studies had ruled out this subgroup since the AMPKK activity purified from rat liver was not dependent on Ca 2+ or calmodulin [25] . The next closest mammalian kinase is LKB1. Mutations in the gene encoding LKB1 had been identified as causative for a rare hereditary form of cancer, termed the Peutz-Jeghers syndrome [26, 27] . Interestingly, LKB1, similar to AMPK, is a heterotrimer, requiring two other proteins, MO25 (mouse protein 25) and STRAD (STE20-related adaptor protein), for catalytic activity [28, 29] . Two independent studies have shown that the upstream kinase activity purified from rat liver corresponds to LKB1 [19, 20] . Furthermore, in cells lacking LKB1 activity, AMPK activity is significantly decreased compared with cells expressing LKB1, and AMPK is not activated by stimuli that normally activate it [19, 20, 30] . The activity of LKB1 itself is not regulated directly by stimuli that activate AMPK, either in cells [19, 20] or in skeletal muscles [31] . Whether other upstream kinases are also involved in the activation of AMPK is still under investigation.
Role of AMPK in regulating whole body metabolism
Activation of AMPK leads to the phosphorylation and regulation of a number of downstream targets that are involved in diverse pathways in numerous tissues in the body, including adipose tissue, liver, muscles and the hypothalamus. AMPK plays a key role in regulating both energy storage and energy utilization, and recent evidence suggests a role for AMPK in the regulation of feeding (Figure 1) . In peripheral tissues, the overall effect of activating AMPK is to increase ATP-producing pathways, e.g. fatty acid oxidation, while inhibiting ATP-utilizing pathways, e.g. fatty acid synthesis. AMPK activity in the hypothalamus can be modulated by hormones, including ghrelin (activation) and leptin (inhibition), by nutritional status and also pharmacologically, e.g. AICAR. Changes in AMPK activity lead to alteration in the expression of NPY. Increased NPY leads to an increase in food intake and a decrease in energy expenditure, whereas decreased NPY has the opposite effect.
The role of AMPK in the central regulation of energy metabolism began to be appreciated only recently. Physiological signals that regulate food intake, e.g. hormones and nutritional status, modulate AMPK activity in the hypothalamus [32] , suggesting that AMPK may be directly involved in the mechanism by which these signals are transduced. Direct experimental evidence that AMPK plays a role in the regulation of feeding comes from studies that show that inhibition of hypothalamic AMPK leads to decreased food intake [32, 33] , whereas activation increases feeding [34] . The effect of AMPK on feeding appears to be mediated, at least in part, by changes in the expression of NPY (neuropeptide Y; Figure 2 ). This emerging area represents an exciting development in the field and there are many important issues to address. For instance, the hormonal regulation of AMPK in the hypothalamus is not understood and the identity of downstream targets from AMPK is unknown. Further research into this area will undoubtedly throw light on these problems.
The importance of AMPK in regulating whole body energy metabolism is also emphasized by studies on α2 KO (knockout) mice. Deletion of α2 results in mild insulin resistance and an insulin-secretory defect [35, 36] . Glucose intolerance in the α2 KO mice is not due to a defect in skeletalmuscle glucose uptake, but probably results from both impaired insulin action and inhibition of insulin secretion owing to increased catecholamine levels in the fed state [35] . The molecular basis for this defect is not understood at present, but may be due to altered sympathetic nervous activity, consistent with a regulatory role for α2 within the central nervous system. In a recent study, α2 KO mice fed with a high-fat diet have been shown to exhibit increased body weight coupled with an increase in fat mass, due to increased size of the pre-existing adipocytes, when compared with wild-type animals [37] . At present, the mechanism underlying this response is not known.
Targets of AMPK in cardiac and skeletal muscles
Owing to space limitations of this review, we will restrict our discussion of the metabolic targets of AMPK to those identified in cardiac and skeletal muscles. For a more comprehensive review of AMPK targets in other tissues, see [1, 17] . Many studies on AMPK have relied on the use of AICAR (5-amino-4-imidazole carboxamide riboside) as a pharmacological activator of the cascade. AICAR is a cell-permeable adenosine analogue that is taken up by cells and phosphorylated to the AMP mimetic ZMP (AICAR monophosphate). A great deal of interest was engendered in AMPK as a potential target in the treatment of Type II (non-insulin-dependent) diabetes when it was reported that perfusion of rat hind limb muscles with AICAR increased glucose uptake and fatty acid oxidation in muscles through a mechanism distinct from that of insulin [38] . The increase in glucose transport was accompanied by increased translocation of the GLUT4 glucose transporter to the plasma membrane [39] . Infusion of AICAR has also been shown to increase muscle 2-deoxyglucose uptake as well as whole body glucose disposal in lean rats in vivo [40] .
AMPK activity is increased in muscles after contraction in response to exercise, a condition that also increases glucose uptake through an insulin-independent mechanism, leading to speculation that AMPK mediates the effect of exercise on glucose transport [41] . Using transgenic mice expressing a dominant-negative form of AMPK in muscles, Birnbaum's group showed that, whereas AMPK was required for the stimulation of glucose uptake in response to AICAR and hypoxia, it was only partially required for that by muscle contraction, suggesting that at least two mechanisms are involved: an AMPK-dependent and AMPK-independent pathway [42] . In a more recent study, it was shown that deletion of either α1 or α2 had no significant effect on contraction-stimulated glucose uptake [36] . Furthermore, the increase in GLUT4 expression in response to exercise and denervation has been reported not to require AMPK [43] . These findings cast serious doubt on the earlier prevailing view that AMPK is involved in the regulation of glucose uptake in skeletal muscles, and it will be important to establish firmly what role AMPK plays in this process in vivo. In heart, inactivation of AMPK by overexpression of dominant-negative α2 significantly decreased ischaemiainduced glucose uptake, exacerbating ATP depletion and increasing the degree of injury due to apoptosis [44, 45] . In addition, inactivation of AMPK prevented the increase in fatty acid oxidation after reperfusion of ischaemic hearts [44] . Activation of AMPK in skeletal and cardiac muscles has also been shown to increase fatty acid oxidation [38, 46] . This correlates with phosphorylation and inactivation of acetyl-CoA carboxylase-2 and a subsequent decrease in the concentration of malonyl-CoA, which relieves the inhibition of carnitine palmitoyl transferase 1 [38, 46] .
In heart, AMPK phosphorylates and activates phosphofructokinase-2 [47] . Activation of phosphofructokinase-2 stimulates the production of fructose-2,6-bisphosphate, an activator of 6-phosphofructo-1-kinase, thus increasing glycolytic flux. This pathway is supposed to be responsible for the increased rate of glycolysis in hearts during ischaemia [47] .
A number of studies suggest that AMPK plays a key role in the regulation of glycogen metabolism. Glycogen synthase is phosphorylated and inactivated by AMPK in vitro [48] and in rat hind limb muscles [49] . Conversely, the activation of AMPK by AICAR in skeletal muscles decreases with an increase in glycogen levels [49] but is increased when muscle cells are incubated in low glucose concentrations correlating with decreased glycogen synthase activity [50] . These findings are indicative of an interaction between glycogen levels and AMPK activity. It is tempting to speculate that the glycogen-binding domain in the β subunit mediates this interaction, although there is no experimental evidence to support this at the present time. As mentioned previously, mutations in γ 2 and γ 3 lead to increased accumulation of glycogen in heart and skeletal muscles respectively. The molecular basis for these effects remains unknown, but implies that AMPK regulates glycogen metabolism in vivo.
Exercise training produces a number of adaptive changes within skeletal muscles that are beneficial to the metabolic syndrome. Long-term administration of AICAR to mice, perfusion of hind-limb muscles with AICAR or overexpression of a constitutively active AMPK in skeletal-muscle cells has been shown to increase the expression of a number of proteins in a manner similar to that of exercise training, e.g. GLUT4, hexokinase II and mitochondrial enzymes [51] [52] [53] . These findings raise the prospect that some of the beneficial effects of long-term exercise might be mediated by AMPK, although the recent observation that AMPK is not required for the increase in GLUT4 expression in response to exercise [43] does not support this hypothesis. Nonetheless, chronic activation of AMPK within muscles, e.g. by pharmacological manipulation, might still be advantageous in metabolic diseases.
In addition to its effects on transcription, AMPK also has a role in translation. mTOR (mammalian target of rapamycin) is a key regulator of protein translation, and signalling through mTOR is increased by growth factors and is decreased with nutrient deprivation. Activation of AMPK during nutrient starvation causes the phosphorylation of mTOR on Ser-2448 and inhibition of activity and phosphorylation of the downstream target p70 S6 kinase, thereby inhibiting protein translation. Phosphorylation of mTOR by AMPK could act as a switch mechanism to integrate signals from nutrient status and growth factors to control the regulation of protein translation [54] . Another way in which AMPK might feed into the mTOR pathway is through the tumour suppressors TSC (tuberous sclerosis complex) proteins 1 and 2. Activation of TSC decreases mTOR activity. Recently, AMPK has been reported to phosphorylate and activate TSC, leading to inhibition of the mTOR pathway [55] .
Summary
Research studies on the AMPK have expanded greatly over the past few years and, at present, show little sign of abating. As more downstream targets are identified, the range of processes that AMPK is linked with continues to increase, e.g. apoptosis, senescence and cancer. The identification of LKB1 as an upstream kinase in the AMPK cascade raises further questions regarding the potential role of AMPK in cell proliferation. The use of transgenic animal models has already started to yield important information regarding the physiological role of AMPK, and development of more refined models, e.g. tissue-specific KOs, will facilitate the elucidation of a role for AMPK in the regulation of cellular processes.
